HRP20110852T1 - PIPERIDINSKI AGONISTI GPCR-a - Google Patents
PIPERIDINSKI AGONISTI GPCR-a Download PDFInfo
- Publication number
- HRP20110852T1 HRP20110852T1 HR20110852T HRP20110852T HRP20110852T1 HR P20110852 T1 HRP20110852 T1 HR P20110852T1 HR 20110852 T HR20110852 T HR 20110852T HR P20110852 T HRP20110852 T HR P20110852T HR P20110852 T1 HRP20110852 T1 HR P20110852T1
- Authority
- HR
- Croatia
- Prior art keywords
- piperidine
- propyl
- oxadiazol
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 229940125633 GPCR agonist Drugs 0.000 title abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims abstract 26
- 150000003839 salts Chemical class 0.000 claims abstract 22
- 208000008589 Obesity Diseases 0.000 claims abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 2
- 235000020824 obesity Nutrition 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- QMSQESRBSZEVLM-OAHLLOKOSA-N 3-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound O1C(C(C)C)=NC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 QMSQESRBSZEVLM-OAHLLOKOSA-N 0.000 claims 1
- ICMKSFZJDNVMGL-MRXNPFEDSA-N 3-[4-[(2r)-4-(4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound O1C(C(C)C)=NC(N2CCC(CC2)[C@H](C)CCOC=2C=CC(=CC=2)S(C)(=O)=O)=N1 ICMKSFZJDNVMGL-MRXNPFEDSA-N 0.000 claims 1
- WMHFRNVJYXYHMU-UHFFFAOYSA-N 3-[4-[3-(3-chloro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound O1C(C(C)C)=NC(N2CCC(CCCOC=3C=C(Cl)C(=CC=3)S(C)(=O)=O)CC2)=N1 WMHFRNVJYXYHMU-UHFFFAOYSA-N 0.000 claims 1
- BZGNKWPKMZGCDV-UHFFFAOYSA-N 3-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound O1C(C(C)C)=NC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 BZGNKWPKMZGCDV-UHFFFAOYSA-N 0.000 claims 1
- COLSBVLYLGYHNK-UHFFFAOYSA-N 3-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-5-propyl-1,2,4-oxadiazole Chemical compound O1C(CCC)=NC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 COLSBVLYLGYHNK-UHFFFAOYSA-N 0.000 claims 1
- VFZLLTFPVWCIQY-UHFFFAOYSA-N 3-[4-[3-(3-methyl-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound O1C(C(C)C)=NC(N2CCC(CCCOC=3C=C(C)C(=CC=3)S(C)(=O)=O)CC2)=N1 VFZLLTFPVWCIQY-UHFFFAOYSA-N 0.000 claims 1
- KJJOJTSYGQMCTR-UHFFFAOYSA-N 3-[4-[3-(3-methyl-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-5-propyl-1,2,4-oxadiazole Chemical compound O1C(CCC)=NC(N2CCC(CCCOC=3C=C(C)C(=CC=3)S(C)(=O)=O)CC2)=N1 KJJOJTSYGQMCTR-UHFFFAOYSA-N 0.000 claims 1
- VRXGLILJFLLDGP-UHFFFAOYSA-N 3-[4-[3-(4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound O1C(C(C)C)=NC(N2CCC(CCCOC=3C=CC(=CC=3)S(C)(=O)=O)CC2)=N1 VRXGLILJFLLDGP-UHFFFAOYSA-N 0.000 claims 1
- QRTLCDQUPUHALP-UHFFFAOYSA-N 3-[4-[3-(4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-5-propyl-1,2,4-oxadiazole Chemical compound O1C(CCC)=NC(N2CCC(CCCOC=3C=CC(=CC=3)S(C)(=O)=O)CC2)=N1 QRTLCDQUPUHALP-UHFFFAOYSA-N 0.000 claims 1
- GOJZISSHNRVZTQ-UHFFFAOYSA-N 3-ethyl-5-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound CCC1=NOC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 GOJZISSHNRVZTQ-UHFFFAOYSA-N 0.000 claims 1
- FAGWQFDQJJTQLD-UHFFFAOYSA-N 3-ethyl-5-[4-[3-(4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound CCC1=NOC(N2CCC(CCCOC=3C=CC(=CC=3)S(C)(=O)=O)CC2)=N1 FAGWQFDQJJTQLD-UHFFFAOYSA-N 0.000 claims 1
- OKCPZOKPEJXTKM-OAHLLOKOSA-N 3-tert-butyl-5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound C([C@@H](C)C1CCN(CC1)C=1ON=C(N=1)C(C)(C)C)COC1=CC=C(S(C)(=O)=O)C(F)=C1 OKCPZOKPEJXTKM-OAHLLOKOSA-N 0.000 claims 1
- DEFUWUWXBZYCTH-MRXNPFEDSA-N 3-tert-butyl-5-[4-[(2r)-4-(4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound C([C@@H](C)C1CCN(CC1)C=1ON=C(N=1)C(C)(C)C)COC1=CC=C(S(C)(=O)=O)C=C1 DEFUWUWXBZYCTH-MRXNPFEDSA-N 0.000 claims 1
- HCLMFPSZNCSUHX-UHFFFAOYSA-N 3-tert-butyl-5-[4-[3-(3-chloro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC(C)(C)C1=NOC(N2CCC(CCCOC=3C=C(Cl)C(=CC=3)S(C)(=O)=O)CC2)=N1 HCLMFPSZNCSUHX-UHFFFAOYSA-N 0.000 claims 1
- YUUSWHOAPSHNQT-UHFFFAOYSA-N 3-tert-butyl-5-[4-[3-(3-methyl-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound C1=C(S(C)(=O)=O)C(C)=CC(OCCCC2CCN(CC2)C=2ON=C(N=2)C(C)(C)C)=C1 YUUSWHOAPSHNQT-UHFFFAOYSA-N 0.000 claims 1
- HOCKOIVSHFOEFS-UHFFFAOYSA-N 3-tert-butyl-5-[4-[3-(4-ethylsulfonyl-3-fluorophenoxy)propyl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound C1=C(F)C(S(=O)(=O)CC)=CC=C1OCCCC1CCN(C=2ON=C(N=2)C(C)(C)C)CC1 HOCKOIVSHFOEFS-UHFFFAOYSA-N 0.000 claims 1
- ZXOXTFAYLUXYKJ-UHFFFAOYSA-N 3-tert-butyl-5-[4-[3-(4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC(C)(C)C1=NOC(N2CCC(CCCOC=3C=CC(=CC=3)S(C)(=O)=O)CC2)=N1 ZXOXTFAYLUXYKJ-UHFFFAOYSA-N 0.000 claims 1
- AJJISMLYIMQAKP-OAHLLOKOSA-N 5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 AJJISMLYIMQAKP-OAHLLOKOSA-N 0.000 claims 1
- UFZGQTYELYCXFZ-MRXNPFEDSA-N 5-[4-[(2r)-4-(3-methyl-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(C)C(=CC=2)S(C)(=O)=O)=N1 UFZGQTYELYCXFZ-MRXNPFEDSA-N 0.000 claims 1
- WLMVBEXOSRILNA-MRXNPFEDSA-N 5-[4-[(2r)-4-(4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=CC(=CC=2)S(C)(=O)=O)=N1 WLMVBEXOSRILNA-MRXNPFEDSA-N 0.000 claims 1
- JCUIBGNUQRNNDK-MRXNPFEDSA-N 5-[4-[(2r)-4-(4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propyl-1,2,4-oxadiazole Chemical compound CCCC1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=CC(=CC=2)S(C)(=O)=O)=N1 JCUIBGNUQRNNDK-MRXNPFEDSA-N 0.000 claims 1
- VLACEOSUCJAWDG-UHFFFAOYSA-N 5-[4-[3-(3-chloro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=C(Cl)C(=CC=3)S(C)(=O)=O)CC2)=N1 VLACEOSUCJAWDG-UHFFFAOYSA-N 0.000 claims 1
- NGTLMTJXHHVFKK-UHFFFAOYSA-N 5-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 NGTLMTJXHHVFKK-UHFFFAOYSA-N 0.000 claims 1
- DPSQJTZWTDOKFO-UHFFFAOYSA-N 5-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 DPSQJTZWTDOKFO-UHFFFAOYSA-N 0.000 claims 1
- IATPCIBOIGPQOH-UHFFFAOYSA-N 5-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propyl-1,2,4-oxadiazole Chemical compound CCCC1=NOC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 IATPCIBOIGPQOH-UHFFFAOYSA-N 0.000 claims 1
- GAONLKXQODVTMM-UHFFFAOYSA-N 5-[4-[3-(3-methyl-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=C(C)C(=CC=3)S(C)(=O)=O)CC2)=N1 GAONLKXQODVTMM-UHFFFAOYSA-N 0.000 claims 1
- XXYKDYFLCGNWMI-UHFFFAOYSA-N 5-[4-[3-(3-methyl-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propyl-1,2,4-oxadiazole Chemical compound CCCC1=NOC(N2CCC(CCCOC=3C=C(C)C(=CC=3)S(C)(=O)=O)CC2)=N1 XXYKDYFLCGNWMI-UHFFFAOYSA-N 0.000 claims 1
- YMTJKYZUSASUQK-UHFFFAOYSA-N 5-[4-[3-(4-ethylsulfonyl-3-fluorophenoxy)propyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound C1=C(F)C(S(=O)(=O)CC)=CC=C1OCCCC1CCN(C=2ON=C(N=2)C(C)C)CC1 YMTJKYZUSASUQK-UHFFFAOYSA-N 0.000 claims 1
- SPJLGAQJXPHCIZ-UHFFFAOYSA-N 5-[4-[3-(4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=CC(=CC=3)S(C)(=O)=O)CC2)=N1 SPJLGAQJXPHCIZ-UHFFFAOYSA-N 0.000 claims 1
- FNFRIJXKHNODKE-UHFFFAOYSA-N 5-[4-[3-(4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propyl-1,2,4-oxadiazole Chemical compound CCCC1=NOC(N2CCC(CCCOC=3C=CC(=CC=3)S(C)(=O)=O)CC2)=N1 FNFRIJXKHNODKE-UHFFFAOYSA-N 0.000 claims 1
- NHLBTHMXWSUWFN-UHFFFAOYSA-N 5-ethyl-3-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound O1C(CC)=NC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 NHLBTHMXWSUWFN-UHFFFAOYSA-N 0.000 claims 1
- CZPITONRODPQDR-UHFFFAOYSA-N 5-tert-butyl-3-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound O1C(C(C)(C)C)=NC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 CZPITONRODPQDR-UHFFFAOYSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700123A GB0700123D0 (en) | 2007-01-04 | 2007-01-04 | GPCR agonists |
| GB0719760A GB0719760D0 (en) | 2007-10-10 | 2007-10-10 | GPCR agonists |
| PCT/GB2008/050010 WO2008081204A1 (en) | 2007-01-04 | 2008-01-04 | Piperidine gpcr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110852T1 true HRP20110852T1 (hr) | 2011-12-31 |
Family
ID=39203133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110852T HRP20110852T1 (hr) | 2007-01-04 | 2011-11-15 | PIPERIDINSKI AGONISTI GPCR-a |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100048632A1 (el) |
| EP (2) | EP2114933B1 (el) |
| JP (1) | JP2010514828A (el) |
| AT (1) | ATE523507T1 (el) |
| BR (1) | BRPI0806498A2 (el) |
| CA (1) | CA2674348A1 (el) |
| CY (1) | CY1112483T1 (el) |
| DK (1) | DK2114933T3 (el) |
| EA (1) | EA015129B1 (el) |
| ES (1) | ES2373181T3 (el) |
| HK (1) | HK1135703A1 (el) |
| HR (1) | HRP20110852T1 (el) |
| PL (1) | PL2114933T3 (el) |
| PT (1) | PT2114933E (el) |
| RS (1) | RS52065B (el) |
| SI (1) | SI2114933T1 (el) |
| WO (1) | WO2008081204A1 (el) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20081849A1 (es) * | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| JP2010539152A (ja) | 2007-09-10 | 2010-12-16 | プロシディオン・リミテッド | 代謝障害の治療のための化合物 |
| GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812649D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| AR077214A1 (es) | 2009-06-24 | 2011-08-10 | Neurocrine Biosciences Inc | Heterociclos nitrogenados y composiciones farmaceuticas que los contienen |
| NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| ITMI20100770A1 (it) | 2010-05-03 | 2011-11-04 | Dipharma Francis Srl | Procedimento per la preparazione di 3-(4-piridinil)-propanolo e suoi intermedi |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| ITMI20100984A1 (it) | 2010-05-31 | 2011-12-01 | Dipharma Francis Srl | Procedimento per la preparazione di ossadiazoli |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| CN103189360A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的非吸湿性盐 |
| WO2012030938A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
| JP6272695B2 (ja) | 2010-09-01 | 2018-01-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| CA2808900A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Fast-dissolve dosage forms of 5-ht2c agonists |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| JP6463631B2 (ja) | 2011-06-09 | 2019-02-06 | ライゼン・ファーマシューティカルズ・エスアー | Ｇｐｒ−１１９のモジュレータとしての新規化合物 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| MX365108B (es) | 2012-06-12 | 2019-05-23 | Chong Kun Dang Pharmaceutical Corp | Derivados piperidina para agonista gpr119. |
| DK3074384T3 (da) | 2013-11-26 | 2019-07-15 | Chong Kun Dang Pharmaceutical Corp | Amidderivater til gpr119-agonist |
| KR101726819B1 (ko) | 2014-10-27 | 2017-04-13 | 동아에스티 주식회사 | Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| DE4222565A1 (de) * | 1992-07-09 | 1994-01-13 | Hoechst Ag | Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen |
| US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| DE4311967A1 (de) * | 1993-04-10 | 1994-10-13 | Hoechst Ag | Smektische Flüssigkristallmischung |
| DE4311968A1 (de) * | 1993-04-10 | 1994-10-20 | Hoechst Ag | Smektische Flüssigkristallmischung |
| ES2140543T3 (es) | 1993-08-13 | 2000-03-01 | Zeneca Ltd | Derivados de tia- y oxadiazol y su uso como fungicidas o insecticidas. |
| WO1997015567A1 (de) * | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
| WO1998006720A1 (fr) | 1996-08-09 | 1998-02-19 | Eisai Co., Ltd. | Derives de benzopiperidine |
| GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
| EP1123391A2 (en) | 1998-09-01 | 2001-08-16 | BASF Aktiengesellschaft | Methods for improving the function of heterologous g protein-coupled receptors |
| US6221660B1 (en) * | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| GB0109103D0 (en) | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
| FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なピラゾール類似体 |
| KR100950430B1 (ko) | 2001-09-21 | 2010-04-02 | 솔베이 파마슈티칼스 비. 브이 | 효력있는 ｃｂ1-길항 작용을 가지는4,5-디하이드로-1ｈ-피라졸 유도체 |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| DK1429761T3 (da) | 2001-09-21 | 2007-02-05 | Solvay Pharm Bv | Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning |
| FR2831883B1 (fr) | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| FR2833842B1 (fr) | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
| WO2003063781A2 (en) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| EP1482794A1 (en) | 2002-03-06 | 2004-12-08 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
| CA2478183C (en) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
| AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
| US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
| ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
| CA2479744A1 (en) | 2002-03-28 | 2003-10-09 | Paul E. Finke | Substituted 2,3-diphenyl pyridines |
| EP1494997A4 (en) | 2002-04-05 | 2007-04-11 | Merck & Co Inc | SUBSTITUTED ARYLAMID |
| FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
| FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
| JP4459629B2 (ja) | 2002-04-12 | 2010-04-28 | メルク エンド カムパニー インコーポレーテッド | 二環式アミド |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| WO2004013120A1 (en) | 2002-07-29 | 2004-02-12 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
| JP4667867B2 (ja) | 2002-08-02 | 2011-04-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換フロ［２，３−ｂ］ピリジン誘導体 |
| AU2003296895A1 (en) | 2002-08-20 | 2004-05-04 | The Regents Of The University Of California | Combination therapy for controlling appetites |
| AR041268A1 (es) | 2002-09-19 | 2005-05-11 | Solvay Pharm Bv | Derivados de la 1h -1,2,4- triazol-3-carboxamida que tienen actividad agonista, agonista parcial, agonista inversa o antagonista del receptor cb 1 de cannabinoide y composiciones farmaceuticas que los contienen |
| EP1546115A4 (en) | 2002-09-27 | 2010-08-04 | Merck Sharp & Dohme | SUBSTITUTED PYRIMIDINES |
| CA2502511A1 (en) | 2002-10-18 | 2004-05-29 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| AU2003300967B2 (en) | 2002-12-19 | 2009-05-28 | Merck Sharp & Dohme Corp. | Substituted amides |
| GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| ES2334565T3 (es) | 2003-01-02 | 2010-03-12 | Hoffmann La Roche | Agonistas inversos del receptor cb 1. |
| PL378244A1 (pl) | 2003-01-02 | 2006-03-20 | F. Hoffmann-La Roche Ag | Pirolilotiazole i ich zastosowanie jako odwrotnych agonistów receptora CB 1 |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| EP1597259B1 (de) | 2003-02-13 | 2008-04-30 | Sanofi-Aventis Deutschland GmbH | Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| EP1599480B1 (de) | 2003-02-13 | 2010-06-30 | Sanofi-Aventis Deutschland GmbH | Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US20040167188A1 (en) * | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| EP1606019A1 (en) | 2003-03-07 | 2005-12-21 | The University Court of The University of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
| KR101154830B1 (ko) | 2003-12-24 | 2012-06-18 | 프로시디온 리미티드 | Ｇｐｃｒ 수용체 효능제로서의 헤테로사이클릭 유도체 |
| CA2586056C (en) | 2004-11-02 | 2012-03-13 | Banyu Pharmaceutical Co., Ltd. | Aryloxy-substituted benzimidazole derivative |
| JP4980928B2 (ja) * | 2004-12-24 | 2012-07-18 | プロシディオン・リミテッド | Ｇタンパク質共役受容体（ｇｐｒ１１６）作動薬および肥満および糖尿病治療のためのその使用 |
| JP5065908B2 (ja) | 2004-12-24 | 2012-11-07 | プロシディオン・リミテッド | Ｇタンパク質結合受容体作動薬 |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| US20090221644A1 (en) | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| WO2007003960A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| WO2007003962A2 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| KR20080025190A (ko) | 2005-06-30 | 2008-03-19 | 프로시디온 리미티드 | Ｇ-단백질 결합된 수용체 효능제 |
| WO2007116229A1 (en) * | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
-
2008
- 2008-01-04 RS RS20110523A patent/RS52065B/en unknown
- 2008-01-04 EA EA200900877A patent/EA015129B1/ru not_active IP Right Cessation
- 2008-01-04 JP JP2009544447A patent/JP2010514828A/ja active Pending
- 2008-01-04 CA CA002674348A patent/CA2674348A1/en not_active Abandoned
- 2008-01-04 BR BRPI0806498-9A2A patent/BRPI0806498A2/pt not_active IP Right Cessation
- 2008-01-04 PT PT08702095T patent/PT2114933E/pt unknown
- 2008-01-04 EP EP08702095A patent/EP2114933B1/en active Active
- 2008-01-04 US US12/522,015 patent/US20100048632A1/en not_active Abandoned
- 2008-01-04 EP EP11174256A patent/EP2377863A1/en not_active Withdrawn
- 2008-01-04 WO PCT/GB2008/050010 patent/WO2008081204A1/en active Application Filing
- 2008-01-04 DK DK08702095.4T patent/DK2114933T3/da active
- 2008-01-04 SI SI200830454T patent/SI2114933T1/sl unknown
- 2008-01-04 AT AT08702095T patent/ATE523507T1/de active
- 2008-01-04 ES ES08702095T patent/ES2373181T3/es active Active
- 2008-01-04 PL PL08702095T patent/PL2114933T3/pl unknown
-
2010
- 2010-04-16 HK HK10103731.6A patent/HK1135703A1/xx not_active IP Right Cessation
-
2011
- 2011-11-15 HR HR20110852T patent/HRP20110852T1/hr unknown
- 2011-11-25 CY CY20111101161T patent/CY1112483T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1112483T1 (el) | 2015-12-09 |
| EP2114933A1 (en) | 2009-11-11 |
| SI2114933T1 (sl) | 2012-01-31 |
| JP2010514828A (ja) | 2010-05-06 |
| HK1135703A1 (en) | 2010-06-11 |
| US20100048632A1 (en) | 2010-02-25 |
| CA2674348A1 (en) | 2008-07-10 |
| EP2114933B1 (en) | 2011-09-07 |
| ES2373181T3 (es) | 2012-02-01 |
| WO2008081204A1 (en) | 2008-07-10 |
| EA200900877A1 (ru) | 2010-02-26 |
| EP2377863A1 (en) | 2011-10-19 |
| DK2114933T3 (da) | 2012-01-02 |
| ATE523507T1 (de) | 2011-09-15 |
| BRPI0806498A2 (pt) | 2014-04-22 |
| PT2114933E (pt) | 2011-12-20 |
| RS52065B (en) | 2012-06-30 |
| PL2114933T3 (pl) | 2012-02-29 |
| EA015129B1 (ru) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110852T1 (hr) | PIPERIDINSKI AGONISTI GPCR-a | |
| JP2010514828A5 (el) | ||
| HRP20110750T1 (hr) | PIPERIDINSKI AGONISTI GPCR-a | |
| ES2376015T3 (es) | Agonistas de gpcr de tipo piperidina. | |
| RU2396269C2 (ru) | Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1) | |
| RU2008109908A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| US7888353B2 (en) | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators | |
| JP2010539152A5 (el) | ||
| US20110178054A1 (en) | Heterocyclic GPCR Agonists | |
| HRP20150355T1 (hr) | Sulfonamidni derivati | |
| PE20141375A1 (es) | Activadores de glucoquinasa | |
| CA2630269A1 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
| JP2004508356A5 (el) | ||
| JP2011500658A5 (el) | ||
| CA2667068A1 (en) | 2-pyridinecarboxamide derivative having gk-activating effect | |
| AR076563A1 (es) | Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica | |
| PE20081532A1 (es) | Compuestos novedosos | |
| AU2005260821A1 (en) | Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| PE20110237A1 (es) | Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1) | |
| BR112012015168B1 (pt) | Derivados de benzamida substituída e composição farmacêutica que os compreende | |
| JP2006500369A5 (el) | ||
| JP2012512252A5 (el) | ||
| RU2010140854A (ru) | Пиридин-2-ильные производные в качестве иммуномодулирующих агентов | |
| PE20120732A1 (es) | Agonistas del receptor de esfingosina-1-fosfato |